2. Signaling Pathways
  3. Epigenetics
  4. METTL3
  5. METTL3 Inhibitor

METTL3 Inhibitor

METTL3 Inhibitors (18):

Cat. No. Product Name Effect Purity
  • HY-134836
    STM2457
    		Inhibitor 99.86%
    STM2457 is a first-in-class, highly potent, selective and orally active METTL3 inhibitor with an IC50 of 16.9 nM. STM2457 can be used for the research of acute myeloid leukaemia (AML).
  • HY-156677
    STC-15
    		Inhibitor 99.90%
    STC-15 is an orally active RNA methyltransferase METTL3 inhibitor with the activity of activating anti-tumor immunity and reshaping the tumor microenvironment. STC-15 inhibits tumor growth by activating anti-cancer immune responses associated with increased interferon signaling and synergizes with T-cell checkpoint blockade. STC-15 can be used in the study of proliferative diseases such as cancer and autoimmune diseases.
  • HY-115717
    UZH2
    		Inhibitor 98.73%
    UZH2 is a potent and selective METTL3 inhibitor with an IC50 value of 5 nM.
  • HY-162080
    METTL1-WDR4-IN-1
    		Inhibitor 98.87%
    METTL1-WDR4-IN-1 (1) is a METTL1-WDR4 inhibitor, with an IC50 of 144 μM.
  • HY-160415A
    WD6305 TFA
    		Inhibitor 98.47%
    WD6305 TFA is a potent and selective METTL3-METTL14 PROTAC degrader. WD6305 TFA has DC50 values of 140 nM and 194 nM for METTL3 and METTL14, respectively. WD6305 TFA inhibits m6A modification and proliferation of AML cells, and induces apoptosis. WD6305 TFA has antitumor activity.
  • HY-P10387A
    RSM3 TFA
    		Inhibitor
    RSM3 TFA, a stapled peptide, is a METTL3-METTL14 inhibitor with an Kd of 3.10 μM. RSM3 TFA inhibits tumor growth while induces cell apoptosis. RSM3 TFA can be used for study of cancer.
  • HY-159604
    METTL3-IN-9
    		Inhibitor
    METTL3-IN-9 (compound C3) is an inhibitor of methyltransferase-like METTL3, an RNA methyltransferase that catalyzes the N6-methyladenosine (m6A) modification of mRNA in eukaryotic cells.
  • HY-153625
    STM2120
    		Inhibitor 99.92%
    STM2120 is a METTL3-METTL14 inhibitor with an IC50 of 64.5 μM.
  • HY-134673B
    UZH1b
    		Inhibitor 99.75%
    UZH1b is an enantiomer of UZH1a (a METTL3 inhibitor). UZH1b is essentially inactive for METTL3 (IC50=28 µM).
  • HY-148467
    METTL3-IN-1
    		Inhibitor
    METTL3-IN-1 (compound 23) is a polyheterocyclic compound, acts as METTL3 inhibitor.
  • HY-148468
    METTL3-IN-2
    		Inhibitor
    METTL3-IN-2 (compound 28) is a METTL3 inhibitor with an IC50 value of 6.1 nM. METTL3-IN-2 inhibits cell proliferation of Caov3 cancer cells.
  • HY-158403
    METTL3-IN-7
    		Inhibitor
    METTL3-IN-7 (F039-0002) is a potent METTL3 inhibitor. METTL3-IN-7 strongly ameliorates dextran sodium sulfate (DSS)-induced colitis. METTL3-IN-7 can be used Inflammatory bowel disease (IBD) research.
  • HY-148469
    METTL3-IN-3
    		Inhibitor
    METTL3-IN-3 (compound 11) is a polyheterocyclic compound, acts as METTL3 inhibitor.
  • HY-P10387
    RSM3
    		Inhibitor
    RSM3, a stapled peptide, is a METTL3-METTL14 inhibitor with an Kd of 3.10 μM. RSM3 inhibits tumor growth while induces cell apoptosis. RSM3 can be used for study of cancer.
  • HY-158404
    METTL3-IN-8
    		Inhibitor
    METTL3-IN-8 (7460-0250) is a potent METTL3 inhibitor. METTL3-IN-8 strongly ameliorates DSS-induced colitis. METTL3-IN-8 can be used Inflammatory bowel disease (IBD) research.
  • HY-156759
    METTL3-IN-5
    		Inhibitor
    METTL3-IN-5 (Compound 13) is a METTL3 inhibitor. METTL3-IN-5 inhibits MOLM-13 growth with an IC50 less than 2 μM. METTL3-IN-5 has weak hERG inhibitory activity (IC50 >30 μM). METTL3-IN-5 can be used for AML research.
  • HY-154997
    7OQL
    		Inhibitor
    7OQL (compound 54) is a selective METTL3 inhibitor (IC50=0.054 µM). 7OQL has the potential to be used in the study of cancer.
  • HY-160415
    WD6305
    		Inhibitor
    WD6305 is a potent and selective METTL3-METTL14 PROTAC degrader. WD6305 has DC50 values of 140 nM and 194 nM for METTL3 and METTL14, respectively. WD6305 inhibits m6A modification and proliferation of AML cells, and induces apoptosis. WD6305 has antitumor activity.